Sionna Therapeutics
Natick
About Sionna Therapeutics
Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $292.0M
- Funding stage: IPO
- Last round: Series C (Mar 2024)
- Ticker: nasdaq:SION
- Website: sionnatx.com
- Phone: 617-819-2020
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/sionna-therapeutics-46895 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.